Sei Investments Co. Purchases 38,740 Shares of Takeda Pharmaceutical Co. $TAK

Sei Investments Co. increased its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 20.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 229,943 shares of the company’s stock after buying an additional 38,740 shares during the period. Sei Investments Co.’s holdings in Takeda Pharmaceutical were worth $4,259,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership lifted its stake in Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after acquiring an additional 2,854,069 shares during the last quarter. UBS Group AG increased its stake in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after purchasing an additional 1,869,323 shares during the last quarter. Qube Research & Technologies Ltd increased its stake in shares of Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after purchasing an additional 1,426,184 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Takeda Pharmaceutical by 98.4% in the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after purchasing an additional 1,143,117 shares during the period. Finally, Voloridge Investment Management LLC raised its holdings in shares of Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after purchasing an additional 880,289 shares during the period. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Up 1.0%

Takeda Pharmaceutical stock opened at $16.72 on Thursday. The stock has a market cap of $53.57 billion, a P/E ratio of 49.17 and a beta of -0.08. The company has a quick ratio of 0.60, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. Takeda Pharmaceutical Co. has a twelve month low of $12.99 and a twelve month high of $18.90. The company’s 50-day moving average price is $16.30 and its two-hundred day moving average price is $17.09.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The company had revenue of $6.90 billion during the quarter. As a group, analysts expect that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TAK shares. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold”.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.